B-cell malignancies treated with targeted drugs and SARS-CoV-2 infection
| Autor: | Maria Stefania Infante, Jon Salmanton-García, Ana Fernández-Cruz, Francesco Marchesi, Ozren Jaksic, Barbora Weinbergerová, Caroline Besson, Rafael F. Duarte, Federico Itri, Toni Valković, Tomáš Szotkovski, Alessandro Busca, Anna Guidetti, Andreas Glenthøj, Graham P. Collins, Valentina Bonuomo, Uluhan Sili, Guldane Cengiz Seval, Marina Machado, Raul Cordoba, Ola Blennow, Ghaith Abu-Zeinah, Sylvain Lamure, Austin Kulasekararaj, Iker Falces-Romero, Chiara Cattaneo, Jaap Van Doesum, Klára Piukovics, Ali S. Omrani, Gabriele Magliano, Marie-Pierre Ledoux, Cristina de Ramon, Alba Cabirta, Luisa Verga, Alberto López-García, Maria Gomes Da Silva, Zlate Stojanoski, Stef Meers, Tobias Lahmer, Sonia Martín-Pérez, Julio Dávila-Vals, Jens Van Praet, Michail Samarkos, Yavuz M. Bilgin, Linda Katharina Karlsson, Josip Batinić, Anna Nordlander, Martin Schönlein, Martin Hoenigl, Zdeněk Ráčil, Miloš Mladenović, Michaela Hanakova, Giovanni Paolo Maria Zambrotta, Nick De Jonge, Tatjana Adžić-Vukičević, Raquel Nunes-Rodrigues, Lucia Prezioso, Milan Navrátil, Monia Marchetti, Annarosa Cuccaro, Maria Calbacho, Antonio Giordano, Oliver A. Cornely, José-Ángel Hernández-Rivas, Livio Pagano |
|---|---|
| Přispěvatelé: | Infante M. S. , Salmanton-García J., Fernández-Cruz A., Marchesi F., Jaksic O., Weinbergerová B., Besson C., Duarte R. F. , Itri F., Valković T., et al., Institut Català de la Salut, [Infante MS] Hematology Deparment, Hospital Universitario Infanta Leonor, Madrid, Spain. [Salmanton-García J] Faculty of Medicine and University Hospital Cologne, Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), University of Cologne, Cologne, Germany. Faculty of Medicine and University Hospital Cologne, Department I of Internal Medicine, Excellence Center for Medical Mycology (ECMM), University of Cologne, Cologne, Germany. [Fernández-Cruz A] Hospital Universitario Puerta de Hierro, Majadahonda, Spain. [Marchesi F] Hematology and Stem Cell Transplant Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy. [Jaksic O] Department of Hematology, University Hospital Dubrava, Zagreb, Croatia. [Weinbergerová B] Department of Internal Medicine, Hematology and Oncology, Masaryk University and University Hospital Brno, Brno, Czechia. [Cabirta A] Servei d’Hematologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Experimental Hematology, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain, Vall d'Hebron Barcelona Hospital Campus, Gilead Sciences, Hematology |
| Jazyk: | angličtina |
| Rok vydání: | 2022 |
| Předmět: |
Investigative Techniques::Epidemiologic Methods::Data Collection::Surveys and Questionnaires [ANALYTICAL
DIAGNOSTIC AND THERAPEUTIC TECHNIQUES AND EQUIPMENT] Internal Diseases Cancer Research SARS-CoV-2 chronic lymphocytic leukemia (CLL) immune system COVID19 infection risk lymphoproliferative diseases (LPD) non-Hodgkin lymphoma (NHL) targeted drugs Sağlık Bilimleri COVID-19 (Malaltia) İç Hastalıkları Clinical Medicine (MED) BİYOKİMYA VE MOLEKÜLER BİYOLOJİ virosis::infecciones por virus ARN::infecciones por Nidovirales::infecciones por Coronaviridae::infecciones por Coronavirus [ENFERMEDADES] Medicine and Health Sciences IDELALISIB Klinik Tıp (MED) 03.02. Klinikai orvostan IBRUTINIB BIOMEDICINA I ZDRAVSTVO. Kliničke medicinske znanosti. Interna medicina Hemic and Lymphatic Diseases::Lymphatic Diseases::Lymphoproliferative Disorders [DISEASES] RNA COVID-19 VACCINE BIOMEDICINE AND HEALTHCARE. Clinical Medical Sciences. Oncology Klinik Tıp OBINUTUZUMAB CHALLENGES Temel Bilimler Life Sciences Virus Diseases::RNA Virus Infections::Nidovirales Infections::Coronaviridae Infections::Coronavirus Infections [DISEASES] Onkoloji ddc Tıp MOLECULAR BIOLOGY & GENETICS Oncology CHLORAMBUCIL Medicine ONKOLOJİ Natural Sciences BIOMEDICINA I ZDRAVSTVO. Kliničke medicinske znanosti. Infektologija Life Sciences & Biomedicine BIOCHEMISTRY & MOLECULAR BIOLOGY Sitogenetik Life Sciences (LIFE) Molecular Biology and Genetics Enquestes Yaşam Bilimleri Health Sciences Trastorns limfoproliferatius Cytogenetic RITUXIMAB BIOMEDICINE AND HEALTHCARE. Clinical Medical Sciences. Internal Medicine Moleküler Biyoloji ve Genetik Science & Technology Internal Medicine Sciences CHRONIC LYMPHOCYTIC-LEUKEMIA técnicas de investigación::métodos epidemiológicos::recopilación de datos::encuestas y cuestionarios [TÉCNICAS Y EQUIPOS ANALÍTICOS DIAGNÓSTICOS Y TERAPÉUTICOS] Dahili Tıp Bilimleri CLINICAL MEDICINE BIOMEDICINE AND HEALTHCARE. Clinical Medical Sciences. Infectology enfermedades hematológicas y linfáticas::enfermedades linfáticas::trastornos linfoproliferativos [ENFERMEDADES] ONCOLOGY EFFICACY Settore MED/15 - MALATTIE DEL SANGUE Yaşam Bilimleri (LIFE) BIOMEDICINA I ZDRAVSTVO. Kliničke medicinske znanosti. Onkologija Kanser Araştırmaları |
| Zdroj: | FRONTIERS IN ONCOLOGY Scientia Infante, M S, Salmanton-García, J, Fernández-Cruz, A, Marchesi, F, Jaksic, O, Weinbergerová, B, Besson, C, Duarte, R F, Itri, F, Valković, T, Szotkovski, T, Busca, A, Guidetti, A, Glenthøj, A, Collins, G P, Bonuomo, V, Sili, U, Seval, G C, Machado, M, Cordoba, R, Blennow, O, Abu-Zeinah, G, Lamure, S, Kulasekararaj, A, Falces-Romero, I, Cattaneo, C, van Doesum, J, Piukovics, K, Omrani, A S, Magliano, G, Ledoux, M-P, de Ramon, C, Cabirta, A, Verga, L, López-García, A, da Silva, M G, Stojanoski, Z, Meers, S, Lahmer, T, Martín-Pérez, S, Dávila-Vals, J, van Praet, J, Samarkos, M, Bilgin, Y M, Karlsson, L K, Batinić, J, Nordlander, A, Schönlein, M, Hoenigl, M, Ráčil, Z, Mladenović, M, Hanakova, M, Zambrotta, G P M, de Jonge, N, Adžić-Vukičević, T, Nunes-Rodrigues, R, Prezioso, L, Navrátil, M, Marchetti, M, Cuccaro, A, Calbacho, M, Giordano, A, Cornely, O A, Hernández-Rivas, J-Á & Pagano, L 2022, ' B-cell malignancies treated with targeted drugs and SARS-CoV-2 infection : A European Hematology Association Survey (EPICOVIDEHA) ', Frontiers in Oncology, vol. 12, 992137 . https://doi.org/10.3389/fonc.2022.992137 Frontiers in Oncology, 12:992137. Frontiers Media SA Frontiers in Oncology, 12:992137. Frontiers Media S.A. Infante, M S, Salmanton-García, J, Fernández-Cruz, A, Marchesi, F, Jaksic, O, Weinbergerová, B, Besson, C, Duarte, R F, Itri, F, Valković, T, Szotkovski, T, Busca, A, Guidetti, A, Glenthøj, A, Collins, G P, Bonuomo, V, Sili, U, Seval, G C, Machado, M, Cordoba, R, Blennow, O, Abu-Zeinah, G, Lamure, S, Kulasekararaj, A, Falces-Romero, I, Cattaneo, C, Van Doesum, J, Piukovics, K, Omrani, A S, Magliano, G, Ledoux, M-P, de Ramon, C, Cabirta, A, Verga, L, López-García, A, Da Silva, M G, Stojanoski, Z, Meers, S, Lahmer, T, Martín-Pérez, S, Dávila-Vals, J, Van Praet, J, Samarkos, M, Bilgin, Y M, Karlsson, L K, Batinić, J, Nordlander, A, Schönlein, M, Hoenigl, M, Ráčil, Z, Mladenović, M, Hanakova, M, Zambrotta, G P M, De Jonge, N, Adžić-Vukičević, T, Nunes-Rodrigues, R, Prezioso, L, Navrátil, M, Marchetti, M, Cuccaro, A, Calbacho, M, Giordano, A, Cornely, O A, Hernández-Rivas, J Á & Pagano, L 2022, ' B-cell malignancies treated with targeted drugs and SARS-CoV-2 infection : A European Hematology Association Survey (EPICOVIDEHA) ', Frontiers in Oncology, vol. 12, 992137 . https://doi.org/10.3389/fonc.2022.992137 Frontiers in Oncology Volume 12 |
| ISSN: | 2234-943X |
| DOI: | 10.3389/fonc.2022.992137 |
| Popis: | Patients with lymphoproliferative diseases (LPD) are vulnerable to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Here, we describe and analyze the outcome of 366 adult patients with chronic lymphocytic leukemia (CLL) or non-Hodgkin Lymphoma (NHL) treated with targeted drugs and laboratory-confirmed COVID-19 diagnosed between February 2020 and January 2022. Median follow-up was 70.5 days (IQR 0-609). Most used targeted drugs were Bruton-kinase inhibitors (BKIs) (N= 201, 55%), anti-CD20 other than rituximab (N=61, 16%), BCL2 inhibitors (N=33, 9%) and lenalidomide (N=28, 8%).Only 16.2% of the patients were vaccinated with 2 or more doses of vaccine at the onset of COVID-19. Mortality was 24% (89/366) on day 30 and 36%(134/366) on the last day of follow-up. Age >75 years (p EPICOVIDEHA has received funds from Optics COMMITTM (COVID-19 Unmet Medical Needs and Associated Research Extension) COVID-19 RFP program by GILEAD Science, United States (Project 2020-8223). |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|